Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Lieneke Fm Ariëns; Jorien van der Schaft; Lotte S Spekhorst; Daphne S Bakker; Geertruida L E Romeijn; Tessa A Kouwenhoven; Marijke Kamsteeg; Angelique N Voorberg; Albert J Oosting; Ilona de Ridder; Annemieke Sloeserwij; Inge Haeck; Judith L Thijs; Marie LA Schuttelaar; Marjolein S de Bruin-Weller

doi:10.1016/j.jaad.2020.08.127

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Lieneke Fm Ariëns, Jorien van der Schaft, Lotte S Spekhorst, Daphne S Bakker, Geertruida L E Romeijn, Tessa A Kouwenhoven, Marijke Kamsteeg, Angelique N Voorberg, Albert J Oosting, Ilona de Ridder, Annemieke Sloeserwij, Inge Haeck, Judith L Thijs, Marie LA Schuttelaar, Marjolein S de Bruin-Weller

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited. Objective: To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis. Methods: Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated. Results: Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was –70.0% (standard deviation 33.2%) and further decreased to –76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment. Limitations: Because of the lack of a control group and observational design, factors of bias may have been induced. Conclusion: Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.

Original language	English
Pages (from-to)	1000-1009
Number of pages	10
Journal	Journal of the American Academy of Dermatology
Volume	84
Issue number	4
Early online date	16 Sept 2020
DOIs	https://doi.org/10.1016/j.jaad.2020.08.127
Publication status	Published - Apr 2021

Keywords

atopic dermatitis
daily practice
disease severity
dupilumab
effectiveness
long-term
safety

Access to Document

10.1016/j.jaad.2020.08.127

Cite this

Ariëns, L. F., van der Schaft, J., Spekhorst, L. S., Bakker, D. S., Romeijn, G. L. E., Kouwenhoven, T. A., Kamsteeg, M., Voorberg, A. N., Oosting, A. J., Ridder, I. D., Sloeserwij, A., Haeck, I., Thijs, J. L., Schuttelaar, M. LA., & de Bruin-Weller, M. S. (2021). Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. Journal of the American Academy of Dermatology, 84(4), 1000-1009. https://doi.org/10.1016/j.jaad.2020.08.127

@article{3b27345d29644c56936a6a27e20842ce,

title = "Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry",

abstract = "Background: Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited. Objective: To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis. Methods: Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated. Results: Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was –70.0% (standard deviation 33.2%) and further decreased to –76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment. Limitations: Because of the lack of a control group and observational design, factors of bias may have been induced. Conclusion: Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.",

keywords = "atopic dermatitis, daily practice, disease severity, dupilumab, effectiveness, long-term, safety",

author = "Ari{\"e}ns, {Lieneke Fm} and {van der Schaft}, Jorien and Spekhorst, {Lotte S} and Bakker, {Daphne S} and Romeijn, {Geertruida L E} and Kouwenhoven, {Tessa A} and Marijke Kamsteeg and Voorberg, {Angelique N} and Oosting, {Albert J} and Ridder, {Ilona de} and Annemieke Sloeserwij and Inge Haeck and Thijs, {Judith L} and Schuttelaar, {Marie LA} and {de Bruin-Weller}, {Marjolein S}",

note = "Funding Information: Funding sources: Supported by Sanofi and Regeneron Pharmaceuticals . Publisher Copyright: {\textcopyright} 2020 Copyright: Copyright 2021 Elsevier B.V., All rights reserved. Funding Information: Funding sources: Supported by Sanofi and Regeneron Pharmaceuticals . Publisher Copyright: {\textcopyright} 2020",

year = "2021",

month = apr,

doi = "10.1016/j.jaad.2020.08.127",

language = "English",

volume = "84",

pages = "1000--1009",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "4",

}

Ariëns, LF, van der Schaft, J, Spekhorst, LS, Bakker, DS, Romeijn, GLE, Kouwenhoven, TA, Kamsteeg, M, Voorberg, AN, Oosting, AJ, Ridder, ID, Sloeserwij, A, Haeck, I, Thijs, JL, Schuttelaar, MLA & de Bruin-Weller, MS 2021, 'Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry', Journal of the American Academy of Dermatology, vol. 84, no. 4, pp. 1000-1009. https://doi.org/10.1016/j.jaad.2020.08.127

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. / Ariëns, Lieneke Fm; van der Schaft, Jorien; Spekhorst, Lotte S et al.
In: Journal of the American Academy of Dermatology, Vol. 84, No. 4, 04.2021, p. 1000-1009.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice

T2 - 52-Week results from the Dutch BioDay registry

AU - Ariëns, Lieneke Fm

AU - van der Schaft, Jorien

AU - Spekhorst, Lotte S

AU - Bakker, Daphne S

AU - Romeijn, Geertruida L E

AU - Kouwenhoven, Tessa A

AU - Kamsteeg, Marijke

AU - Voorberg, Angelique N

AU - Oosting, Albert J

AU - Ridder, Ilona de

AU - Sloeserwij, Annemieke

AU - Haeck, Inge

AU - Thijs, Judith L

AU - Schuttelaar, Marie LA

AU - de Bruin-Weller, Marjolein S

N1 - Funding Information: Funding sources: Supported by Sanofi and Regeneron Pharmaceuticals . Publisher Copyright: © 2020 Copyright: Copyright 2021 Elsevier B.V., All rights reserved. Funding Information: Funding sources: Supported by Sanofi and Regeneron Pharmaceuticals . Publisher Copyright: © 2020

PY - 2021/4

Y1 - 2021/4

N2 - Background: Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited. Objective: To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis. Methods: Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated. Results: Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was –70.0% (standard deviation 33.2%) and further decreased to –76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment. Limitations: Because of the lack of a control group and observational design, factors of bias may have been induced. Conclusion: Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.

AB - Background: Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited. Objective: To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis. Methods: Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated. Results: Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was –70.0% (standard deviation 33.2%) and further decreased to –76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment. Limitations: Because of the lack of a control group and observational design, factors of bias may have been induced. Conclusion: Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.

KW - atopic dermatitis

KW - daily practice

KW - disease severity

KW - dupilumab

KW - effectiveness

KW - long-term

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=85101137092&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2020.08.127

DO - 10.1016/j.jaad.2020.08.127

M3 - Article

C2 - 32946967

SN - 0190-9622

VL - 84

SP - 1000

EP - 1009

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 4

ER -

Ariëns LF, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. Journal of the American Academy of Dermatology. 2021 Apr;84(4):1000-1009. Epub 2020 Sept 16. doi: 10.1016/j.jaad.2020.08.127

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this